Mazin Abdelghany

Statistics

Publications

Citations

1.7K

H-Index

Active since

2020

Affiliations

University of California, San Francisco(Current)

Chan Zuckerberg Initiative (United States)

Harvard University

University of Colorado Denver

Duke University

Mazin Abdelghany is an author at University of California, San Francisco specializing in placebo-controlled efficacy assessment, infectious disease pharmacotherapy, and pharmacotherapy.

ORCID

Publications per year

2020–2024

Publications

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Robert Gottlieb, Carlos Vaca, Roger Paredes et al. · New England Journal of Medicine · 2021 · 1.3K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +13

Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults

Katrina Kalantar, Lucile Neyton, Mazin Abdelghany et al. · Nature Microbiology · 2022 · 143 citations · Full text

Veterinary Medicine, Clinical Sciences, Molecular Medicine +17

Metagenomic prediction of antimicrobial resistance in critically ill patients with lower respiratory tract infections

Paula Hayakawa Serpa, Xianding Deng, Mazin Abdelghany et al. · Genome Medicine · 2022 · 116 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Obesity Is Associated With Pulmonary Hypertension and Modifies Outcomes

R Frank, Jeff Min, Mazin Abdelghany et al. · Journal of the American Heart Association · 2020 · 91 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +11

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia

Jane A. O’Halloran, Emily R. Ko, Kevin J. Anstrom et al. · JAMA · 2023 · 67 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +11

1–5 of 8